Beijing Hotgen Biotech Hits Day High with 4.66% Surge in Stock Price

Beijing Hotgen Biotech Co., Ltd. has experienced a notable increase of 4.66% on March 5, 2026, reaching an intraday high of CNY 127.46. This performance stands in contrast to the China Shanghai Composite, which declined by 1.26% on the same day. Over the past year, Beijing Hotgen has shown impressive growth, with a remarkable 76.76% increase compared to the broader market's 22.49%. However, the company has faced challenges in recent quarters, reporting negative results for the last 12 consecutive periods. The latest figures indicate a significant decline in net sales by 4.41%, alongside a net profit of CNY -75.78 million, which has decreased by 58.81%. Despite these hurdles, the stock has demonstrated resilience over longer time frames, with a 375.13% increase over the past five years. The company's market capitalization stands at CNY 12,588 million, positioning it as a large-cap player in the pharmaceuticals and biotechnology sector. Investors may want to consider these mixed performance indicators as they assess the company's current standing in the market.